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Most aging men and many young men have reduced circulating testosterone levels, 
referred to as hypogonadism. Hypogonadism is estimated to affect about 5 million American 
men, including both aged and young. Low testosterone can have negative effects on mood, 
cognition, cardiovascular health, energy, libido, muscle mass, and bone density.  Leydig cells are 
the testicular cells responsible for testosterone biosynthesis.  A number of cellular changes have 
been identified in the steroidogenic pathway of aged Leydig cells that are associated with reduced 
testosterone formation, including reductions in luteinizing hormone (LH)-stimulated cAMP 
production, the cholesterol transport proteins steroidogenic acute regulatory (STAR) protein and 
translocator protein (TSPO), and downstream steroidogenic enzymes of the mitochondria and 
smooth endoplasmic reticulum. Many of the changes in steroid formation that characterize aged 
Leydig cells can be elicited by the experimental alteration of the redox environment of young 
cells, suggesting that changes in the intracellular redox balance may cause reduced testosterone 
production. As yet, cause-effect relationships have not been established, however. 
Reduced glutathione (GSH), the most abundant intracellular small molecule thiol present 
in mammalian cells, serves as a potent intracellular antioxidant and is particularly abundant in 
Leydig cells. GSH decreases significantly as Leydig cells age. Given the abundance of GSH in 
Leydig cells, we hypothesized that the experimental depletion of GSH would result in an 
increasingly pro-oxidant intracellular environment, and that this would cause reduced 
steroidogenic function. Buthionine sulfoximine (BSO), a specific γ-glutamylcysteine synthetase 
inhibitor, can block the rate-limiting step of GSH biosynthesis, and by doing so deplete the 
intracellular GSH pool in both cultured cells and whole animals. To test the effect of decreased 
GSH on steroid formation, we first cultured MA-10 Leydig cells with BSO short-term (24 hours). 
This treatment reduced intracellular levels of GSH somewhat but had no effect on progesterone 
production by these cells at this early time. Nor did treatment of the cells with tert-butyl 
hydroperoxide (t-BuOOH, 2 hours), an oxidant. However, when the GSH-depleted cells 
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subsequently were exposed acutely to t-BuOOH, intracellular reactive oxygen species 
concentration was significantly increased, and this was accompanied by reductions in steroid 
production. These results suggested that alteration of the intracellular redox environment can 
result in the increased sensitivity of MA-10 cells to oxidative stress under circumstances in which 
the cells have reduced antioxidant capacity. In a second series of studies, cells were cultured for 
days to weeks with BSO alone. Over time, at times after GSH was reduced, steroid synthesis 
decreased, reminiscent of natural aging of primary Leydig cells. These results suggest that, as in 
aging, exposure to an increasingly pro-oxidant environment, over time, can have a negative 
impact on Leydig cell steroidogenic function, and that, indeed, increases in oxidative stress 
contribute to or cause the reduced testosterone production that characterizes Leydig cells aging.  
As of yet, the molecular mechanisms by which aging results in an altered redox environment 
remains unclear.  Also uncertain is the molecular mechanism by which reductions in GSH and 
other antioxidant molecules in Leydig cells, and thus increased oxidative stress, elicit reduced 
sensitivity to LH and thus reduced steroid formation. 
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Introduction 
Many males experience significant decreases in serum testosterone levels by their fourth 
or fifth decade of life, clinically referred to as hypogonadism [1, 2]. Primary hypogonadism 
occurs when Leydig cells, the testosterone producing cells of the testis, fail to respond adequately 
to luteinizing hormone (LH) from the anterior pituitary gland to initiate steroid synthesis [3, 4]. 
Studies have suggested that this is in large part due to altered LH receptor-G protein coupling at 
the Leydig cell plasma membrane [3, 4]. 
Although the mechanism by which age-related defects occur remains uncertain, there is 
evidence that changes in the redox balance within the Leydig cells are involved. For example, 
numerous studies have suggested that imbalance of prooxidants and antioxidants within cells can 
lead to DNA, protein and/or lipid damage, and thus to functional changes [5, 6]. Cells produce 
reactive oxygen species (ROS) during normal metabolism. In steroidogenic cells, ROS 
production would be expected to be particularly high because in addition to the mitochondrial 
electron transport chain, steroid hydroxylations by cytochrome P450 enzymes produce ROS [7, 
8]. This may have significance for Leydig cell function because of the detrimental effects that 
ROS can have on critical components of the steroidogenic pathway [9-11]. As Leydig cells age, 
the antioxidant defense molecules superoxide dismutase-1 and -2, glutathione peroxidase, and 
glutathione (GSH) are significantly reduced [12, 13]. Additionally, the superoxide content of 
aging Leydig cells is significantly increased compared to young Leydig cells [14]. Lipid 
peroxidation also increases, perhaps as a consequence of changes in the redox environment [12]. 
These results, though correlative, suggest that alteration in the redox environment of aged Leydig 
cells may be involved in the reduced testosterone formation that characterizes these cells. 
Because GSH is so integrally involved in maintaining the cellular redox environment, its 
role in Leydig cell aging is of high interest [12]. It is our belief that there exists a correlation 
between diminished levels of GSH and diminished steroid synthesis in aged Leydig cells, and that 
oxidative stress induced by an improperly maintained redox environment is the chief factor 
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behind reduced LH receptor coupling sensitivity. The primary goal of this thesis is to determine 
precisely the effects an altered redox environment with reduced levels of GSH can have on 
Leydig cell health, measured as a function of steroid synthesis. A previous study of Nrf2 
knockout mice studied the effects of removing all major antioxidant pathways in mice on their 
Leydig cell antioxidant capacity and steroidogenesis [15]. It was found that Nrf2-/- mice 
experienced increased levels of oxidative stress at a 3 months (early age), which was followed by 
a significant drop in serum testosterone levels at 8 months (middle age) as opposed to 24 months 
(old age) in wild type mice, indicating that reduced antioxidant capacity precedes a decline in 
steroidogenesis [15].  
While these data are crucial to understanding the role of oxidative stress in Leydig cell 
aging, there is a redundancy of roles between many of the antioxidants Nrf2 regulates, and not all 
antioxidants involved in the Nrf2 pathway are diminished with age [12, 15]. The experiments that 
were undertaken here were designed to distinguish GSH as a key factor in preventing the events 
that lead to Leydig cell decline. In order to do so, we conducted two sets of experiments using 
MA-10 cells, a mouse tumor Leydig cell line that produces progesterone rather than testosterone. 
These cells are simple to culture and monitor [16]. In a first set of experiments, we attempt to 
discern the effects of GSH depletion followed by short-term exposure to the oxidant t-BuOOH on 
steroid synthesis. The idea behind this is that acute exposure of cells with an altered redox 
environment to a stressor may mimic the effects of aging in several regards. In a second set of 
experiments, we attempt to observe the effects of long-term GSH depletion on steroid synthesis, 
another model for Leydig cell aging. It is hypothesized that MA-10 cells will be highly 
susceptible to oxidative stress and diminished steroid synthesis following GSH depletion and also 
that long-term GSH depletion will precede a decline in steroid synthesis, similar to what 






Testosterone is a steroid hormone recognized for its role in masculinization of the body 
as well as its support of spermatogenesis. It is the primary male sex hormone and targets a diverse 
array of cell types throughout the body. It is first synthesized by males in utero, and is essential 
for the development of external genitalia and sex characteristics, both directly and indirectly 
through the actions of its metabolites [3, 17]. In the adult body it has a wider range of roles but is 
chiefly involved in virilization. 
Testosterone elicits numerous physiologic and mental effects, some potent and long term 
such as the induction of puberty and male development, and others more transient and short term 
such as regulating libido and sexual activity. Changes in both interstitial and serum testosterone 
are associated with numerous health states and conditions that can have an impact on fertility, 
metabolism, lean muscle mass, and psychological state [18-20]. Numerous studies also exist 
assessing the possibility for an impact of testosterone on cardiovascular health, mental health and 
neurodegenerative disease, prostate health, gut biome composition, and the immune system [21-
25].  
As aging occurs in the adult male, a noticeable decrease in serum and intra-testicular 
testosterone occurs, likely due to a lifetime of wear brought upon the Leydig cells of the testis 
through the process of steroidogenesis [4, 26]. Steroidogenesis is a highly ATP consumptive 
process and also involves heavy use of cytochrome p450 enzymes [27]. The combination of these 
two factors over a lifetime may put Leydig cells at elevated risk for oxidative damage, ironically 
affecting their ability to synthesize steroid.  As a consequence, a significant population of adult 
males experience a decline in testosterone levels by their fourth or fifth decade of life and are 
either subject to or at high risk for obesity, osteoporosis, frailty, fatigue, erectile dysfunction, 
depression, and general feelings of malaise [28]. This state of having low testosterone is referred 
to as hypogonadism, and the vast majority of males experience it to some extent as they age. 
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Steroidogenesis 
Testosterone is a lipid hormone, synthesized through a series of reactions regulated by the 
hypothalamic-pituitary-gonadal axis. The hypothalamus has the capacity to assess levels of 
circulating serum testosterone and is activated by low concentrations to signal to the pituitary 
gland. Neurons of the hypothalamus secrete gonadotropin-releasing hormone (GnRH) through the 
portal vasculature system that connects it to the anterior pituitary gland, thus inducing it to secrete 
both follicle-stimulating hormone (FSH), which is involved in spermatogenesis, and luteinizing 
hormone (LH), which sets steroidogenesis into motion [1, 29, 30]. 
Upon release from the anterior pituitary into the bloodstream, LH reaches the Leydig 
cells of the testis and acts on their surface receptors. Leydig cells possess the cellular machinery 
required of steroidogenesis, and are the primary producer of testosterone in the male body [27]. 
They arise from a stem cell found in the interstitial compartment of the testis [3, 31]. This cell is 
undifferentiated and is thought to have the capacity for asymmetric division to produce both 
another stem cell and the first cell in the Leydig cell lineage, the progenitor Leydig cell. These 
cells are competent to produce large amounts of testosterone metabolites, but not testosterone 
itself [3, 31]. The progenitor Leydig cells differentiate into immature Leydig cells, and the latter 
into adult Leydig cells at the onset of puberty; the adult cells produce testosterone as their major 
product and reside in the interstitial compartment of the testis between tubules [31, 32].  
Leydig cells contain G-protein-coupled receptors (GPCR) on their cell surface that are 
involved in the initiation of steroidogenesis. The receptor itself is a seven-pass transmembrane 
protein that associates with a G-protein. The G-protein is hetero-trimeric, consisting of three 
subunits: alpha, beta, and gamma [33]. The beta and gamma subunits are typically found bound 
together, and the alpha subunit interacts with the G-protein, the beta-gamma subunits, and a 
molecule of GDP when in its inactive form [4, 33, 34].  
Many of the mechanisms behind steroidogenesis and the down stream effects of LH-
receptor coupling can be observed in Figure 1. Ligand binding activates the receptor and the 
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alpha subunit, initiating an exchange of the bound GDP for GTP. The Alpha subunit then 
dissociates from the receptor and beta-gamma subunit to activate the enzyme adenylyl cyclase 
[34]. Upon activation, adenylyl cyclase functions to convert ATP to cyclic AMP (cAMP), a 
secondary messenger molecule that triggers further downstream effects of the steroidogenic 
pathway [33, 35]. As long as the activated alpha subunit remains bound, adenylyl cyclase will 
remain active. Over time, inherent GTPase properties of the alpha subunit will convert the bound 
GTP to GDP thus shutting off the pathway [4, 33, 34]. 
Adenylyl cyclase activation and cAMP generation activate protein kinase A, an enzyme 
that initiates a signaling cascade that in turn activates CREB, a transcription factor that is 
involved in Leydig cell function [36]. cAMP also facilitates steroidogenesis by aiding in the 
import of cholesterol into the mitochondria, which is the rate-determining step of the pathway 
[37, 38]. Because free circulating cholesterol is toxic, it is often stored in the plasma membrane in 
an esterified form [33, 39]. cAMP acts by phosphorylating and activating hormone-sensitive 
lipase (HSL), an enzyme that cleaves cholesterol-esters into free cholesterol so that it may then be 
used for testosterone synthesis [33]. Like cAMP, HSL is also involved in the protein interactions 
that then bring cholesterol into the mitochondria [40].  
Prior to entering the mitochondria, cholesterol interacts with both Translocator Protein 
(TSPO) and Steroidogenic Acute Regulatory protein (StAR) to gain entry into the inner 
mitochondrial membrane so that the enzymatic processes of steroidogenesis can initiate [33, 41, 
42]. Evidence suggests that StAR is responsible for binding free cholesterol outside the 
mitochondria and transferring it to the outer membrane where it then binds TSPO, which transfers 
it to the inner membrane [35]. 
In the inner membrane, cholesterol is converted into pregnenolone by CYP11A1, a 
cytochrome P450 enzyme that cleaves the C-27 side chain of the cholesterol molecule [37]. Once 
generated, pregnenolone is translocated to the smooth endoplasmic reticulum to undergo further 
enzymatic modification. 3-Beta Hydroxysteroid Dehydrogenase (3b-HSD) converts pregnenolone 
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into progesterone, after which progesterone is subsequently converted into 17α-
hydroxyprogesterone by the enzyme 17α-hydroxylase. 17α-hydroxyprogesterone is then 
enzymatically modified by C17-20 lyase to yield the androgen androstenedione. The final step in 
steroidogenesis is the conversion of androstenedione into testosterone by 17-ketosteroid reductase 
[43]. Leydig cells then excrete testosterone where it can act on nearby Sertoli cells within the 
seminiferous tubules to support spermatogenesis or can enter the blood stream and in this way 
can reach and act on a wide variety of effector cells.  
High levels of circulating testosterone feed back negatively on the hypothalamus and 
anterior pituitary gland to inhibit release of GnRH, FSH, and LH. This in turn shuts down 
steroidogenesis, which may only be reactivated once testosterone levels are sufficiently low [25, 
41]. Accordingly, pulsatility of LH is key for maintaining proper steroidogenesis, and several 
studies suggest that improper LH pulsatility is associated with aging and poor steroid synthesis 
[30, 35, 44]. 
Testosterone synthesis however is not entirely limited to the Leydig cells of the testis. 
Steroid hormones are produced with high frequency in the adrenal cortex of the adrenal gland, 
and due to shared enzymes between these pathways, up to 10% of all circulating testosterone in 
adult males result from conversion of adrenal steroids, such as aldosterone [45]. This is highly 
important due to the potential for impact on androgen sensitive diseases, such as prostate cancer 
[45]. 
 
The Effects of Testosterone on the Body 
 Because testosterone, as well as other steroid hormones, is lipophilic, it is capable of 
passing through cell membranes into the cytoplasm with ease where it can then act on the 
androgen receptor [17]. The androgen receptor is a member of the nuclear receptor superfamily 
and exists inactive and bound to heat-shock chaperone proteins prior to activation [46]. 
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Structurally, the receptor is a protein that contains a ligand binding domain specific for 
androgens, a DNA binding domain that recognizes the nucleotide sequences of androgen 
responsive elements, and an amino-terminal activation domain [46]. 
Upon the binding of testosterone or other androgens to their receptor, the chaperone 
proteins dissociate. Activated and phosphorylated, the ligand bound androgen receptor 
translocates to the nucleus where it forms a homodimer that serves as a transcription factor and 
triggers gene expression and protein synthesis [46]. Depending on the particular stage of life and 
target tissue, testosterone can induce a wide range of effects. In utero testosterone exposure is key 
for the development of the male body [47]. Prior to any major sexual differentiation, the fetus has 
a bi-potential gonad that can develop into either the male or female reproductive tract, and 
eventually the SRY gene of the Y chromosome in males encodes for fetal Leydig cell 
development [17]. These cells then produce testosterone that promotes the formation of the 
Wolffian duct, which eventually becomes the testis [17, 47]. Furthermore, testosterone can be 
converted by the enzyme 5a-reductase into Dihydrotestosterone (DHT), a more potent androgen 
specific to tissues that do not respond to testosterone, and promotes development of the prostate 
and urethra, as well as the masculinization of external genitalia [17].  
 This relationship between androgen action and masculinity continues again in puberty, 
where sudden spikes in testosterone synthesis induce virilization. During puberty, increased 
GnRH and thusly LH pulsatility begin, and androgens mediate the development of secondary 
sexual characteristics that are typified by muscle, hair, and overall body growth [28, 30].  
The effects of androgens on muscle are perhaps their most known and pronounced activity in the 
body. Testosterone is a regulator of many metabolic processes, and causes dose-dependent 
increases in skeletal muscle mass and volume, fat-free body mass, strength, and power [48, 49]. 
Studies suggest that it is also directly responsible for increases in Insulin-like Growth Factor 1 
(IGF-1), hemoglobin and erythropoiesis, concentration of high-density lipoprotein cholesterol, 
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and sexual desire and activity [48]. Conversely, low levels of testosterone have been associated 
with a reversal of the aforementioned trends. 
 Several concerns with regard to testosterone exist surrounding potential negative effects 
on cardiovascular and prostate health. Because circulating testosterone can be converted to DHT 
that acts on the prostate, concerns have been voiced over the ability of testosterone to increase 
prostate specific antigen (PSA) secretion as well as induce benign prostatic hyperplasia (BPH) 
[28, 48].  
 
Testosterone Regulation of Spermatogenesis 
 The creation and development of viable gametes in the testis is a dynamic and lengthy 
process that is initiated at the onset of puberty and is continuous throughout the life of all healthy 
adult males. Early spermatogenesis takes place within the epithelial lining of the seminiferous 
tubules of the testis, with millions of sperm developing in syncytium [50]. Sperm develop from 
progenitor stem cells called spermatogonia, which are capable of dividing through mitosis to 
produce both a copy of themselves and cells that enter a differentiation pathway [50]. 
Differentiation of these cells results in the entry of cells into meiosis during which primary 
spermatocytes divide to form two secondary spermatocytes which then undergo meiosis II to 
yield four spermatids that can then differentiate into sperm [50].  
This entire process occurs on the basal-lamina-lumen axis of the tubules, with more 
immature cells found at the walls of the tubules and mature sperm well into the interior. These 
sperm then exit the lumen of the seminiferous tubules and enter the epididymis where they 
develop and gain the capacity for fertilization [50].  
The presence of FSH and intra-testicular testosterone are crucial for the proper 
maintenance of spermatogenesis. FSH is involved in regulation of spermatogenesis through its 
actions on Sertoli cells, somatic cells of the seminiferous tubules around which immature sperm 
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are supported and developed [50]. Studies show that inhibition of FSH and LH have a negative 
impact on spermatogenesis, and can induce Azoospermia, the absence of viable sperm [29].  
Because Leydig cells lie in the interstitial space in between the seminiferous tubules, when 
testosterone reaches the cells of the testis that contain androgen receptors such as Sertoli cells, 
peritubular cells, and Leydig cells themselves, the concentration is much higher than in any other 
region of the body [29]. In fact, intra-testicular testosterone concentration is approximately 30 
times greater than in serum, and the lower limit of testosterone required to sustain 
spermatogenesis is still over ten times greater than serum levels [29]. Once below this limit 
however, apoptosis of spermatocytes is induced due to lack of androgen receptor nuclear 
localization and the subsequent gene expression that maintains it, thus indicating that 
spermatogenesis is an androgen-dependent process [29, 38]. 
 Although much is unknown about the specific actions of androgens on Sertoli cells to 
support spermatogenesis, it is known that the relationship between Sertoli cell androgen receptor 
expression and testosterone concentration is unique. Studies using the Brown Norway rat as a 
model organism have shed tremendous light on the processes of Leydig cell function and aging 
due to strikingly similar paths of development and senescence between it and humans [5]. Studies 
involving this rat have observed that decreased levels of testosterone down-regulate Sertoli cell 
nuclear androgen receptor expression but have no effect on androgen receptor mRNA levels. This 
implies that a major role of testosterone in the testis is regulating the translation of the androgen 
receptor, which eventually induces spermatogenesis [38].  
 
Hypogonadism 
 Male hypogonadism is the state of having low serum testosterone, which in turn can be 
detrimental to mental health, metabolic processes, and sexual function among many other issues. 
It can also lead to impairment of spermatogenesis, which manifests itself as azoospermia or 
oligospermia. It is perhaps most commonly attributed to aging, but can also be caused by injury 
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or congenital defects that include but are not limited to: metabolic deficiencies, gene mutations, 
improper migration of kisspeptin neurons, exposure to phthalates and endocrine disruptors, and 
Androgen Insensitivity Syndrome [17, 30, 41].  
Regardless of its source, hypogonadism manifests itself in two forms – primary and 
secondary – that both feature major disruptions of the hypothalamic-pituitary-gonadal axis and 
either induce low serum testosterone or make the body incapable of responding to it whatsoever. 
Primary hypogonadism occurs due to errors of the testis, where Leydig cells are incapable of 
properly responding to LH signaling. When a consequence of aging, testosterone is still 
synthesized, but in significantly diminished amounts. Secondary hypogonadism features 
irregularities of the hypothalamus and pituitary gland where GnRH or LH is not released in 
adequate amounts in response to low serum testosterone. Often as a result of low intratesticular 
testosterone, developing sperm are deprived of the signaling required to support spermatogenesis, 
resulting in subsequent infertility. Hypogonadism is a serious public health issue and a major 
medical concern for those whose quality of life has been significantly impacted as consequence of 
low testosterone, as well as young hypogonadal men that desire to father children. Consequently, 
large amounts of resources are being used to understand, treat, and prevent it. 
 
The Effects of Leydig Cell Aging on Male Reproductive Health 
 Many of the health issues and symptoms attributed to aging such as increases in adiposity 
and decreases in energy, mood, muscle mass, libido, and even cognitive function, have a strong 
association with decreases in serum testosterone. While it is certain that aging takes a toll on 
steroidogenesis, whether or not these symptoms are caused by decreased serum androgens or are 
simply correlated to them remains unclear. What has been elucidated however, is that there is no 
significant loss of LH from the anterior pituitary gland with age, as serum LH either increases or 
remains unchanged over time [35]. This is peculiar because it implies that the loss of 
steroidogenic capacity is solely due to Leydig cell dysfunction. 
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 More studies using the Brown Norway rat have demonstrated that stimulating aged males 
with exogenous LH is not sufficient to increase serum testosterone levels to that of a young male 
[35]. As a result of these findings, a large amount of research has gone into understanding the 
differences between young and old Leydig cells, as well as which steps in the steroidogenic 
process are susceptible to breaking down with age. It was found that stimulating Leydig cells with 
cAMP was able to restore serum testosterone to youthful levels. Since cAMP is only involved in 
steroidogenesis upon the activation of the LH receptor, this finding indicates that not only does 
decreased Leydig cell sensitivity stem from the inability to respond to LH signaling, but also that 
this step can be bypassed [35]. Further analysis of LH signaling has revealed both a deficiency in 
the ability of the LH receptor to activate adenylyl cyclase and of cholesterol to translocate into the 
inner mitochondrial membrane. The latter issue is likely related to observed decreases in TSPO 
and StAR in aged Leydig Cells [35].  
 The involvement of cyclooxygenases has also been linked to the decline of testosterone 
synthesis in Leydig cells [3]. Cyclooxygenases are enzymes that function to metabolize 
arachidonic acid in cells, and Cyclooxygenase-2 (COX2) in particular has also been found to be 
inhibitory of steroidogenesis [51, 52]. Because LH signaling and subsequent cAMP production 
trigger the release of arachidonic acid in Leydig cells, COX2 protein expression steadily follows 
LH stimulation [3, 52]. Although the concepts behind LH signaling inducing both steroidogenesis 
and the COX2 expression that serves to inhibit it are conflicting in nature, Brown Norway rats 
have been shown to exhibit heightened amounts of COX-2 with age, thus suggesting it as another 
possible cause of age-induced decline in serum testosterone [52].  
  
Leydig Cell Aging and Oxidative Stress 
While much is yet to be discovered regarding the source of the malfunction of the 
proteins integral to steroidogenesis, researchers have attempted to form a link between the decline 
of Leydig cells and the ability of reactive oxygen species (ROS) to induce cellular damage [53]. 
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ROS are oxygen based molecules that either possess a free radical or are a minor reaction away 
from doing so, such as hydrogen peroxide, superoxide, and free hydroxyl radical [4]. ROS have a 
unique penchant for inducing chain reactions that strip molecules of electrons and can induce 
doubles strand breaks in DNA that damage it beyond repair. ROS also induce lipid peroxidation 
and protein damage, and the accumulation of their actions have been known to trigger many of 
the symptoms of aging such as loss of cell function, cell death, and even cancer [4, 53].  
The vast majority of intercellular ROS are generated as a byproduct of the electron transport 
chain during oxidative phosphorylation [53]. The electron transport chain is a series of protein 
complexes located about the mitochondrial membrane that uses successive redox reactions to 
convert molecular oxygen into energy for the cell, primarily in the form of ATP [53]. As oxygen 
traverses the electron transport chain, there are two major points in which ROS generation can 
occur: Complex I and Complex III. These complexes feature quinonoids and flavonoids, electron 
and proton transferring molecules of the mitochondria that are heavily responsible for the 
incidental generation of ROS [50]. 
In complex I, NADH transfers 2 electrons through a series of iron-sulfur clusters to 
ubiquinone, yielding ubiquinol. Slippage of electrons here generates semiquinone, a radical ion of 
ubiquionol that can convert O2 to O2- (superoxide). In Complex III cytochrome b reduces a 
molecule of ubiquinone to ubiquinol, one electron at a time, with semiquinone radical anion 
formed temporarily as an intermediate in the process [53, 54, 55].  
Slippage of electrons and superoxide synthesis occur so infrequently that superoxide 
accounts for less than 1% of electron transfer from NADH to oxygen [54, 56]. Nevertheless, even 
a small amount of superoxide has the potential to initiate chain reactions that damage DNA. 
Superoxide contributes further to potential oxidative stress through its deactivation of aconitase, 
succinate dehydrogenase, and NADH-ubiquinone oxidoreductase [50], which are enzymes in the 
transport chain that contain iron-sulfur clusters among other metals. This deactivation frees iron 
and or copper ions for use in the Fenton reaction to generate free hydroxyl radical [55]. In the 
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Fenton reaction, hydrogen peroxide is reduced by iron or copper ions to yield two hydroxyl 
radicals. Hydroxyl radical is significantly more dangerous to the cell than superoxide and can 
incur substantial peroxidative damage to proteins, lipids, and DNA.  
A typical cell however has multiple mechanisms in place to remove ROS. Superoxide 
dismutases (SOD) are a family of enzymes that are essential for the removal of superoxide [57, 
58]. They catalyze the conversion of superoxide to hydrogen peroxide, a much more stable and 
less reactive molecule. Glutathione peroxidase can then catalyze the reduction of hydrogen 
peroxide to water by reduced glutathione (GSH). Likewise, catalase can enzymatically convert 
hydrogen peroxide to water and oxygen [57, 58]. Without these antioxidants, hydrogen peroxide 
produced from SODs may be subjected to the Fenton reaction. 
The free radical theory of aging suggests that despite these many mechanisms of ROS 
removal, repeat and acute exposure over a lifetime facilitates the degradation of the cell [12, 53, 
54, 55]. This is especially relevant to Leydig cells because steroidogenesis is a highly ATP 
consumptive process. Much data exist demonstrating a correlation between ATP and testosterone 
synthesis in Leydig cell mitochondria [14, 27]. While inhibition of the mitochondrial electron 
transport chain produces a markedly large drop in the generation of ATP, it is also shown to 
suppress testosterone synthesis, implying that the electron transport chain is the driving force 
behind steroidogenesis rather than glycolysis [27]. Cells that are dependent on glycolysis for 
energy rather than oxidative phosphorylation are likely to be exposed to lower amounts of ROS. 
Accordingly so, it is logical that a cell such as the spermatozoa, which is responsible for the 
passing on of genetic material and is also created from frequently dividing cells, would be 
inclined to use glycolysis as a means of energy [27]. Leydig cells however rarely turnover, and 
this may indicate their preference for a less safe but more efficient process for the generation of 
energy [3] 
Leydig cells and other steroidogenic cells are at an elevated risk of experiencing 
oxidative stress and subsequent lipid peroxidation because of the free radicals they generate 
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during steroidogenesis in addition to oxidative phosphorylation [12]. It has been shown that free 
radicals inhibit steroid synthesis by interfering with cholesterol transport into the mitochondria as 
well as the functions of p450 enzymes [12, 59-64]. As expected, LH has been linked to increased 
amounts of ROS in Leydig cells. Furthermore, LH has also been found to be involved in 
activating the cellular response to oxidative damage in Leydig cells [4]. Stimulating rats with LH 
increases gene expression for numerous anti-oxidant pathways, particularly Nrf2, a transcription 
factor that is a master regulator of the cell’s oxidative stress response pathway [4].  
 Further support of the effects of long-term wear on Leydig cell steroidogenesis is found 
in hormone suppression studies. Through use of Silastic implants, contraceptive amounts of 
testosterone were given to young rats to halt steroidogenesis and thusly put their Leydig cells in a 
state of dormancy [25]. After the removal of these implants, aged rats were found to synthesize 
testosterone at levels comparable to young rats, reaffirming that age related deficiency of 
testosterone is initiated by the long-term use of the cell’s steroidogenic machinery [25]. While 
long-term suppression of LH in humans to prevent Leydig cell aging is impractical, these studies 
leave room for the idea that a diet or regimen heavily involving antioxidants has the potential to 
reverse or prevent the causes of Leydig cell aging. 
A Cao et al. study on antioxidant expression in young and aged rat Leydig cells showed 
that aged Leydig cells, in comparison to young, had decreased expression of (GSH), while other 
non-enzymatic antioxidant levels (vitamin A, vitamin E, and oxidized glutathione) remained 
unchanged [12]. This suggests that there is an age related loss of GSH. Since oxidized glutathione 
(GSSG) levels remained unchanged, perhaps the balance between the two affects cellular 
susceptibility to oxidative stress. The same study found that enzymatic antioxidant SODs, 
glutathione peroxidase, and catalase were all also down in aged cells. GSH is integral to 
maintaining the cellular redox environment, where it serves as a reducing agent in the 
mitochondria while GSSG functions as an oxidizing agent. If the ratio of the two becomes heavily 
skewed in favor of GSSG, it can create an oxidizing environment that perhaps allows reactive 
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oxygen species to thrive and prevents their reduction to more stable, less harmful molecules [65, 
66]. Furthermore, Glutathione is also involved indirectly in other antioxidant processes, such as 
maintenance of vitamins E and C in their reduced forms, where they are able to attenuate harm 
from ROS [67, 68]. Taken together, GSH depletion and poor maintenance of the cellular redox 
environment with age may be a driving factor of Leydig cell aging and loss of steroidogenic 
function. 
The effects of oxidative stress on DNA are only one of many other factors that contribute 
to aging, including but not limited to telomere shortening and the build up of naturally occurring 
DNA mutations. Nevertheless, the potential for ROS to damage cells is so large and evident that 
oxidative stress is generally perceived as a major contributing factor for aging [12, 14, 34]. Lipid 
peroxidation induced by reactive oxygen species is of particular interest for Leydig cell aging 
because the LH receptor is located within the lipid membrane of the cell. Theoretically, lipid 
membranes rapidly turn over and the LH receptor should be continuously translated as necessary. 
Therefore, decreased sensitivity of LH receptor coupling and its ability to be bypassed suggest 
that if ROS are indeed responsible for decreased steroidogenesis in aged cells, they may be acting 
specifically in the lipid membrane damaging the LH receptor, or acting on the regions of DNA 
encoding the ligand binding region of the LH receptor.  Careful observations of the mechanism(s) 
behind the regulation of the cellular redox environment as well as specificity of ROS for 
particular organelles is necessary to further understand the process of Leydig cell steroidogenic 
decline as well as aging at large. 
 
Glutathione Structure, Synthesis, and Regulation 
 Glutathione is a tripeptide molecule consisting of glycine, cysteine, and glutamic acid. It 
is synthesized via two successive ATP dependent reactions by the enzymes gamma-
glutamylcysteine synthetase and glutathione synthetase. It functions as a powerful reducing agent 
and is heavily involved in the maintenance of the cell’s redox environment. Its main functions 
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within the cell are based upon the interactions of its thiol group (S-H), which has the ability to 
serve as a proton donor. It is through critical reactions concerning the donation and acceptance of 
protons and electrons that it is able to demonstrate its antioxidant capacity and assist in the 
regulation of cellular homeostasis. In the presence of ROS, such as hydrogen peroxide, the 
enzyme glutathione peroxidase catalyzes the conversion of hydrogen peroxide to water using 
GSH as a cofactor [69]. The reaction catalyzed by glutathione peroxidase is annotated as such:  
2GSH + H2O2 ! GSSG + 2H2O [50].  
 Once GSH has donated its electron, it then possesses a free radical ion with the potential 
to damage molecules. To prevent such damage, one free radical ion possessing glutathione 
molecule can bind with another to form glutathione disulfide, the oxidized state of glutathione 
(GSSG) [50]. The enzyme glutathione reductase is then used to restore GSH, by catalyzing the 
reaction: GSSG + NADPH + H+ ! 2GSH + NADP+ [50, 70]. Up to 98% of glutathione exists in 
its reduced form, and it is the proper maintenance of the GSH:GSSG balance that determines a 
cell’s ability to adequately respond to oxidative stress and in effect limit aging [66, 71]. The ratio 
of GSH:GSSG is a strong indicator of overall cell health [65]. A strong correlation exists between 
decreased levels of GSH and some disease states associated with aging such as Parkinson’s 
disease and Alzheimer’s disease [66]. An excess of glutathione can also be detrimental to cells, 
with heightened levels being associated with tumor cell resistance to alkylating agents. Potential 
treatment for this can be found through use glutathione inhibitors such as buthionine sulfoximine 
(BSO), a chemotherapeutic agent that inhibits glutamylcysteine synthetase and thus prevents 
glutathione synthesis [72].  
 
Materials and Methods 
Chemicals 
 L-buthionine-sulfoximine (BSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), Waymouth’s MB/752 medium, horse serum, and tert-butyl hydroperoxide (t-
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BuOOH) were from Sigma-Aldrich (St. Louis, MO). Progesterone antibody was from ICN (Costa 
Mesa, CA). Progesterone was from Steraloids (Newport, RI). M-199 medium was from 
Invitrogen (Carlsbad, CA). Bovine LH (USDA-bLH-B-6) was provided by the U.S. Department 
of Agriculture Animal Hormone Program (Beltsville, MD). Testosterone was from Steraloids 
(Newport, RI).  
 
MA-10 Cell Studies  
The MA-10 mouse Leydig tumor cell line was a generous gift from Dr. Mario Ascoli 
(University of Iowa, Iowa City, IA). The cells were cultured in Waymouth’s MB/752 medium 
containing 15% horse serum and 5% CO2 at 34°C. Although Waymouth’s MB/752 medium 
contains a relatively high concentration of GSH, BSO treatments in the present studies depleted 
intracellular GSH. MA-10 cells were plated onto 60 x 15 mm plates in Waymouth’s MB/752 
culture medium with 15% horse serum.  
In the first set of experiments, cells were plated into 24 well plates. After 24 hours, 
100µM BSO was added to the medium.  After 24 hours of BSO incubation, the medium in 
control and BSO treated wells was removed for subsequent treatment of the cells with t-BuOOH 
and LH. The cells were assayed for GSH by methods outlined below. 
 Control and BSO treated cells were incubated with maximally stimulating LH (10ng/ml) 
and tert-butyl hydroperoxide (t-BuOOH) of increasing concentrations (0µM, 6.25µM, 12.5µM, 
25µM, and 50µM) in DMEM/F12-M199 culture medium with .01% BSA. M-199 medium is a 
cholesterol-containing medium that contains low GSH. After 2 hours, the medium was collected 
for the purpose of progesterone assays (RIA). Media from 4 different experiments were analyzed 
for each treatment.  Next, both groups (i.e. control and BSO- treated) were cultured with 
maximally stimulating LH (10ng/ml) alone in DMEM/F12-M199 culture medium. After 1 hour, 
the medium was collected for progesterone assays. Media from 4 different experiments were 
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analyzed for each treatment.  The cells were frozen in -80⁰C, and assayed for MTT reduction 
(cell viability). Another set of cells treated with BSO/t-BuOOH as above were allowed to 
undergo a 48 hour period of recovery in Waymouth’s MB/752 medium containing 15% horse 
serum and 5% CO2 at 34°C, after which they were cultured with maximally stimulating LH (10 
ng/ml) in DMEM/F12-M199 culture medium for 2 hours. Some cells were frozen (80⁰C) and 
others assayed for MTT reduction. Media from 4 different experiments were analyzed for 
progesterone for each treatment.  
  In another set of experiments, cells were cultured long-term in the presence of BSO. 
Every four days for four weeks, cells were treated with one of three concentrations of BSO (25 
µM, 50µM or 100 µM). 24 hours after BSO treatment, cell samples were both collected for GSH 
analysis and plated into a 24 well plate where they were incubated with maximally stimulating 
LH (10ng/ml) alone in DMEM/F12-M199 culture medium. After 1 hour, the medium was 
collected for progesterone assays. Progesterone concentrations were determined by 
radioimmunoassay (RIA) and expressed as nanograms/ml culture medium. 
 
GSH assay 
Cells were lysed in 5% metaphosphoric acid and sonicated. Protein was precipitated by 
centrifugation at 13,000g for 30 minutes. The supernatant was diluted 10 fold with sodium 
phosphate buffer (0.1M, pH-8.0, with 5mM EDTA). Diluted samples (10µl) were incubated with 
10 µl of o-phthalaldehyde (in methanol) and 180 µl of phosphate buffer for 15 min at room 
temperature. Fluorescence was read with a BioRad luminescence spectrometer (excitation 
wavelength 350nm and emission wavelength 420nm). The cellular GSH content was calculated 
using a GSH standard curve that was run concurrently. Cells from 4 different experiments were 




 Data are expressed as the mean ± standard error of the mean (SEM). For two group 
comparisons, Student’s t-test was used. For multi-group comparisons, group means were 
evaluated by two-way ANOVA. If group differences were revealed by ANOVA (P<0.05), 
differences between individual groups were determined with the Tukey’s test using SigmaStat 
software (Systat Software Inc., Richmond, CA). Values were considered significant at P<0.05. 
 
RESULTS 
Effects of short-term BSO treatment on intracellular GSH and steroidogenesis in MA-10 cells 
In order to demonstrate the effects of short-term BSO treatment on intracellular GSH 
levels, MA-10 cells were incubated with increasing concentrations of BSO in culture medium 
(25µM, 50µM, 100µM) for 24 hours. Figure 2A shows concentration-dependent decreases in 
intracellular GSH with increasing amounts of BSO when compared to control cells. BSO at 
25µM  produced a 22% decrease in GSH compared to control, with 50µM and 100µM producing 
28% and 33% decreases, respectively. Following 24-hour BSO treatment, cells were washed free 
of BSO and incubated with maximally stimulating LH (10ng/µl) for 2 hours. Figure 2B shows no 
major differences in progesterone formation and thus no effect of short-term (24 h) BSO 
treatment.  
 
Effect of an oxidizing agent on steroidogenesis in an altered redox environment 
 To determine whether an altered redox environment resulting from reduction in GSH 
would sensitize the cells to subsequent exposure to an oxidant, MA-10 cells first were cultured in 
100 µM BSO for a 24 hour period. Cells cultured with BSO for 24 hours were then cultured for 2 
hours with increasing concentrations of t-BuOOH (0µM, 6.25µM, 12.5µM, 25µM, or 50µM) and 
with maximally stimulating LH. As also shown in Figure 2B, when cells were cultured in the 
absence of t-BuOOH, there was no difference in progesterone produced between control cells and 
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cells treated with BSO for 24 hours (Fig. 3). However, as also shown in Figure 3, when control 
and BSO-treated cells were incubated with 6.25µM t-BuOOH, both the control and BSO-treated 
cells showed decreases in progesterone production compared to control cells that did not receive 
t-BuOOH. At 12.5µM t-BuOOH, progesterone production decreased by both BSO pretreated and 
the non-BSO treated controls. However, a significantly greater decrease in progesterone 
production was seen by the BSO-treated cells. This same pattern was true at 25 and 50 µM t-
BuOOH; progesterone decreased more in cells that had been pre-treated with BSO.  
  
Effects of continued BSO treatment on intracellular GSH and steroidogenesis in MA-10 cells  
 After observing that short term (24 hour) BSO incubation had little affect on 
progesterone production, but that BSO incubation followed by t-BuOOH caused a large decrease 
in progesterone, we sought to determine if long-term GSH depletion alone would have an effect 
on progesterone synthesis. In order to observe this, cells were treated with increasing amounts of 
BSO in culture medium (0µM, 25µM, 50µM, 100µM) for 24-hour periods every 4 days for 28 
days. After each treatment, cells were assessed for GSH content and for their ability to produce 
progesterone in response to maximally stimulating LH for 2 hours. Figure 4 shows that as was the 
case for a 24-hour incubation with BSO, incubations with BSO over the course of 8 days had 
minor effects on GSH and also had no effect on  progesterone production. 
Figure 5 shows cells after  incubations with BSO over the course of 12 days of culture. 
As seen in Figure 5A, cells treated with 25µM BSO showed a 40% decrease in GSH and a 26% 
decrease in progesterone (5B). Incubation of cells with 50µM BSO resulted in a 28% decrease in 
GSH and decreased progesterone output by 36%. Cells given 100µM BSO showed a 28% 
decrease in GSH and a 39% decrease in progesterone. Figure 6 shows cells after 28 days of BSO 
treatments. Decreases were seen in GSH, as at 12 days. Decreases in progesterone were 40% at 
25µM BSO,  and with 50 and 100 µM BSO,  45% and 29%, respectively.  
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Longitudinal effects of BSO incubation on GSH and progesterone synthesis 
 Figures 7, 8, and 9 concern the longitudinal effects of incubating cells in a given 
concentration of BSO on GSH, over time. Figure 7 shows changes in intracellular GSH levels of 
cells given 25µM BSO at each 4-day interval for 28 days. Figures 8 and 9 show the longitudinal 
effects of BSO treatment at 50µm and 100 µM respectively. Data are expressed both as GSH  
concentration (A) and as percent of control (B), where control cells were not given BSO but were 
cultured for the same amount of time as BSO treated cells. According to Figure 7, continued 
incubation of cells in 25µM BSO did not have a consistent effect on GSH levels, as 
concentrations varied between treatments without forming a trend. When compared to control 
cells, however, 25µM BSO cells consistently exhibited diminished levels of GSH. Similar results 
are seen in figures 8 and 9 for both 50µM and 100µM BSO treated cells; intracellular GSH levels 
varied in these cells throughout BSO incubations, but still were consistently lower than that of 
control cells.  
 Figure 10 shows changes in progesterone synthesized by cells given 25µM BSO at each 
4-day interval for 28 days. While the concentration of progesterone appears to diminish from 
days 8-28, when observed as a percent of control these cells showed decreased levels of 
progesterone on days 12 and 28 compared to control, which remained throughout all subsequent 
BSO incubations. A similar trend is observed in figures 11 and 12, which show progesterone 
levels over time in cells cultured in 50 and 100µM BSO, respectively. Concentration of 
progesterone appears to decrease over time, but when observed as a percent of control there are 
only slight changes in progesterone from days 0-8. By 12 days of culture through 28 days 
however, there is a large decrease in progesterone in comparison to control cells. 
 Figure 13A assesses the implications of long term repeat exposure to BSO on 
intracellular GSH, showing GSH levels for each concentration of BSO given to cells, 
longitudinally, as a percent of control. All values for each group show a decrease in GSH from 
control in response to all concentrations of BSO; however the extent to which GSH decreases 
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varies between treatment groups as well as days of treatment. Figure 13B assesses the 
implications of long term repeat exposure to BSO on progesterone, showing progesterone levels 
for each concentration of BSO given to cells, longitudinally, as a percent of control. All cells 
show largely diminished levels of progesterone by 12 days of culture, maintained throughout 28 
days. These findings indicate a relatively early reduction in GSH is followed later by reduced 
progesterone levels. However, this diminished progesterone appears to occur without strong 
correlation to the concentration of BSO. The data obtained are summarized in Tables 1 and 2. 
 
Discussion 
With aging, serum levels of testosterone typically are reduced [43, 73-76]. In Brown 
Norway rats as in men, reduced serum testosterone usually is not in response to reduced LH, but 
rather to a primary testicular defect. Thus, in the case of Brown Norway rats, Leydig cells 
isolated from the testes of aging rats produce less testosterone in response to luteinizing hormone 
(LH) than cells from young rats [73]. Although the cause(s) of reduced testosterone formation 
remains uncertain, it is known that aging cells, in general, can undergo deleterious changes in 
response to exposure to reactive oxygen-induced free radical reactions [53, 77-79]. Superoxide 
and other reactive oxygen species (ROS) are produced by the mitochondrial electron transport 
chain during oxidative phosphorylation [80]. In the case of Leydig cells, ROS are produced from 
this source, but in addition, Leydig cell cytochrome P450 enzymes catalyze the oxidation of 
metabolic intermediates in the steroidogenic pathway, thus generating additional free radicals 
[81]. Thus, mitochondrial superoxide production has been shown to increase in aging Leydig 
cells [14], and the antioxidant defense molecules superoxide dismutase-1 and -2, glutathione 
peroxidase, and GSH to decrease [12, 13]. Lipid peroxidation increases with age in Leydig [12] 
and adrenal cells [82], two of the major steroidogenically active cells in the body.  It seems 
reasonable to conclude from these studies that imbalance in the oxidant/antioxidant environment 
of aging Leydig cells, perhaps by causing oxidative damage to proteins, lipids, and/or DNA [83], 
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might be the cause of reduced testosterone formation by these cells. However, these studies 
identified correlations, not cause-effect relationships.  
    Based upon  a strong correlation between a diminished antioxidant response and cell 
aging, we made antioxidant depletion a focal point of the experiments that we describe herein [3, 
12, 34, 61]. More specifically, a study indicating that GSH is an antioxidant significantly depleted 
in adult rat Leydig cells led us to investigate a possible correlation between GSH depletion, 
oxidative stress, and age-induced decline in steroid production. As such, the overarching 
objective of this thesis was to better understand the relationship between oxidative stress and 
Leydig cell aging, measured as a function of steroidogenic output.  
Using MA-10 cells, we attempted to create a model for Leydig cell aging by 
manipulating the cell’s redox environment to mimic that of an aged cell, and to determine if that 
would have an effect on steroidogenesis, either immediately or with a delayed onset. Specifically, 
the experiments concerning GSH depletion sought to test three different parameters concerning 
oxidative stress and cell function. The first parameter concerned increasing the oxidant load of 
MA-10 cells by introducing a stressor (t-BuOOH). The second concerned increasing the oxidant 
load while reducing the ability of the cell to respond to stress by reducing intracellular GSH (t-
BuOOH with BSO). The third concerned reducing the ability of the cell to deal with intracellular  
stress over an extended period of time (BSO over time). We hypothesized that following GSH 
depletion, MA-10 cells would be highly susceptible to oxidative stress induced by t-BuOOH and 
exhibit diminished steroid synthesis; and that long-term GSH depletion, even in the absence of a 
stressor, would precede a decline in steroid synthesis, similar to what has been observed to occur 
in vivo. 
In order to induce oxidative stress and alter the Leydig cell redox environment to an 
extent similar to that seen in aged cells, MA-10 cells were treated with BSO to reduce GSH. The 
24 hour treatment of MA-10 cells with BSO demonstrated that BSO causes an immediate, though 
small, reduction in intracellular GSH levels and thus is capable of altering a cell’s redox 
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environment. This relatively rapid GSH depletion had little to no effect on steroidogenesis. To 
determine whether an altered intracellular GSH environment affected the susceptibility of the 
cells to oxidative stress,  MA-10 cells that had been incubated in BSO for 24 hours were then 
exposed to the stressor t-BuOOH. A rapid, concentration-dependent reduction in progesterone 
was seen. Interestingly, when control cells (cells not treated with BSO) were given increasing 
amounts of t-BuOOH, progesterone was found to decrease but to a significantly lesser extent than 
in cells pre-treated with BSO. This suggests that BSO pre-treatment exacerbated the decline in 
progesterone synthesis initiated by T-BuOOH alone.  
At low concentrations of t-BuOOH (6.25 and 12.5 µM) there were relatively small 
differences observed between control and BSO pre-treated cells’ ability to synthesize steroid. 
However at higher concentrations of t-BuOOH (50 and 100 µM), there was a marked decline in 
progesterone from BSO pre-treated cells in comparison to control cells. These results suggest  
that in a normal redox environment, with plentiful levels of GSH, the effects of free radical 
exposure to cells are minimal. However, in an environment with diminished levels of GSH, MA-
10 cells become highly susceptible to free radical damage and, as a consequence, experience 
diminished steroid synthesis. This also implies that simply having an altered redox environment is 
not immediately sufficient to diminish steroid synthesis. Either an external stressor of some kind, 
and/or time, apparently are required for there to be an impact on the steroidogenic machinery of 
the cell. The inefficacy of BSO to have an immediate effect on steroidogenesis can be explained 
by the fact that cells contain pathways in addition to GSH that are also used for the removal of 
reactive oxygen species [57, 58]. In depleting GSH, these alternative pathways may be able to 
compensate for its absence and maintain a relatively healthy cell. When exposed to t-BuOOH, 
however, these GSH depleted cells might easily exhaust all other means of reactive oxygen 
species removal. These data suggest that there is a certain threshold of an altered redox 
environment wherein the effects of oxidative stress manifest in the form of reduced steroid 
synthesis. 
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While this is of great importance for understanding some of the factors involved in 
Leydig cell aging and decline, aging is of course a process that occurs over time and must be 
studied as such in order to be fully understood. To do so, further experiments were conducted to 
determine the effects of consistent GSH depletion by BSO over time, in the absence of the 
external stressor t-BuOOH. MA-10 cells were exposed to one of three concentrations of BSO (25, 
50, or 100 µM) from 24 hours to 28 days and were assayed at 24 hours, 4 days, 8 days, 12 days 
and 28 days for both GSH and progesterone, the latter in response to maximal stimulation by LH. 
Consistent with the previous set of studies, after 24 hours of BSO, cells exhibited diminished 
GSH levels but no decline in progesterone. This persisted through days 4 and 8. By day 12, 
diminished levels of GSH were accompanied by a large decline in progesterone, and this 
continued through day 28. It is worth noting that while all cells given BSO exhibited diminished 
levels of GSH, there was little concentration-dependent correlation observed between the 
concentration of BSO given and concentration of GSH observed. Nevertheless, cells with 
diminished GSH concentrations still exhibited reduced progesterone synthesis, implying that over 
time, even a modestly altered anti-oxidant environment is able to hinder steroidogenesis.  
These results are quite consistent with a set of studies concerning Nrf2 knockout mice, 
which demonstrated that when Leydig cell antioxidant capacity is attenuated by knocking out 
Nrf2,  it is eventually followed by a decrease in the ability to synthesize testosterone [15]. Taken 
together, these results fall in line with the free radical theory of aging, and further serve to 
provide evidence that Leydig cell senescence may indeed be induced by the accumulation of 
oxidative stress over a lifetime. 
There are some curious observations, concerns, and limiting factors in the data. The 
extent to which GSH was depleted in the long-term BSO treated MA-10 cells differed in some 
respects with what occurs physiologically in aged cells. Leydig cells isolated from old Brown 
Norway rats have been shown to exhibit up to a 60% decrease in GSH in comparison to young 
cells, while BSO treated MA-10 cells showed decreases of up to only 40% [12]. These data 
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suggest, however, that even relatively modest GSH depletion may be sufficient to decrease 
steroidogenesis in cells over time. Also of note is the type of cell line used in these studies. MA-
10 Leydig cells are a transformed tumor cell line, which turn over regularly and frequently. 
Theoretically, as cells are given fresh nutrients, their internal stores of proteins, lipids, and other 
important biomolecules should be restored each time they replicate. Therefore any damage 
incurred by reactive oxygen species to the aforementioned biomolecules might not manifest in 
subsequent generations unless direct damage to the cell’s DNA is occurring. High susceptibility 
of the DNA region encoding the LH receptor to oxidative stress may be a factor in diminished 
steroidogenesis in spite of relative good health of the cell overall. 
Another highly plausible scenario is that by treating these rapidly turning over cells with 
BSO, a known toxin, BSO resistant cells could have been selected for and otherwise normal MA-
10 cells could have died. It is also possible that cells capable of functioning in spite of decreased 
GSH levels were selected for as well. Neither scenario is ideal given that these data are intended 
to reflect the responses of a typical Leydig cell. 
Avenues to explore in the future studies include assaying long-term BSO treated cells for 
steroidogenic enzymes to determine the components of the steroidogenic pathway that are  
deficient and thus lead to reduced steroid synthesis. It would be of a particular significance if the 
step(s) in the pathway most affected by GSH depletion was LH-receptor coupling because this is 
the step affected in Leydig cells of the aging testis. Testing MA-10 cells for the ability to recover 
from long-term GSH depletion is of interest as well, specifically observing whether GSH and 
progesterone levels in these cells can be restored from BSO removal or even with the added  
presence of  an inducer of GSH. 
In summary, the results presented herein support the hypothesis that a cause-effect 
relationship exists between reduced antioxidant capacity after GSH depletion by BSO, and 
presumably increased reactive oxygen species (ROS). This, in turn, would expose Leydig cells, 
whether primary or MA-10 cells, to higher oxidative stress levels, which, over time, would result 
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in accelerated reductions in steroidogenic function.  Indeed, such changes occur in vivo, over 
time, with aging in both rats and mice. The mechanisms by which loss of antioxidant capacity and 



























Figure 1: Illustration of the molecular events involved in testosterone production by Leydig 
cells. Luteinizing hormone (LH) binds to receptors on the Leydig cell plasma membrane, thereby 
initiating a cascade of events that includes increased intracellular cAMP formation, translocation 
of cholesterol into the mitochondria (with the involvement of steroidogenic acute regulatory 
protein and translocator protein), association of cholesterol with P450scc, production of 
pregnenolone from cholesterol in the mitochondria, translocation of pregnenolone from the 
mitochondria to the smooth endoplasmic reticulum, and conversion of pregnenolone to 
testosterone via a series of reactions in the smooth endoplasmic reticulum. 
  
Zirkin, B.R. and H. Chen, Regulation of Leydig Cell Steroidogenic Function During Aging. 
Biology of Reproduction, 2000. 63(4): p. 977-981.
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Figure 2: Effect of 24-hour BSO treatment on intracellular GSH and progesterone 
synthesis. Cells were treated with 0, 25, 50, or 100 µM BSO for a 24 hour period. Cells were 
then assayed for GSH (A). The remaining cells  were stimulated with LH for 2 hours for 





Figure 3: Effect of GSH depletion plus t-BuOOH on progesterone production by MA-10 
Leydig Cells. The cells were treated with BSO alone for 24 hours then treated for an additional 2 
hours with increasing concentrations of the oxidant t-BuOOH. Cells were then incubated with 
maximally stimulating LH and assayed for progesterone. Data are presented as progesterone in 
ng/ml (A) and as percent of control (B). Altering the redox environment of the cells with BSO 
plus t-BuOOH resulted in reduced progesterone, dependent upon t-BuOOH dose. (Figure taken 
from the Master’s thesis of Keerti Balachandran) 
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Figure 4: Effect BSO treatment on intracellular GSH and progesterone synthesis at 8 days 
culture. Cells were treated with 0, 25, 50, or 100 µM BSO for a 24 hour period. Cells were then 
assayed for GSH (A). The remaining cells were stimulated with LH for 2 hours for progesterone 





Figure 5: Effect of BSO treatment on intracellular GSH and progesterone synthesis at 12 
days culture. Cells were treated with 0, 25, 50, or 100 µM BSO for a 24 hour period. Cells were 
then assayed for GSH (A). The remaining cells were stimulated with LH for 2 hours for 
progesterone assay (B). Figures A and B show GSH and progesterone levels respectively on the 





Figure 6: Effect of BSO treatment on intracellular GSH and progesterone synthesis at 28 
days culture. Cells were treated with 0, 25, 50, or 100 µM BSO for a 24 hour period. Cells were 
then assayed for GSH (A). The remaining cells were stimulated with LH for 2 hours for 
progesterone assay (B). Figures A and B show GSH and progesterone levels respectively on the 





Figure 7: Effect of 25µM BSO incubation on GSH depletion over time. The cells were treated 
with 25 µM BSO for 24 hour period every 4 days for 28 days. Following BSO treatment, cells 
were assayed for GSH. Data are shown as ng GSH per 108 cells (A) and as percent of control 





Figure 8: Effect of 50µM BSO incubation on GSH depletion over time. The cells were treated 
with 50 µM BSO for 24 hour period every 4 days for 28 days. Following BSO treatment, cells 
were assayed for GSH. Data are shown as ng GSH per 108 cells (A) and as percent of control 




Figure 9: Effect of 100µM BSO incubation on GSH depletion over time.  The cells were 
treated with 100 µM BSO for 24 hour period every 4 days for 28 days. Following BSO treatment, 
cells were assayed for GSH. Data are shown as ng GSH per 108 cells (A) and as percent of 




Figure 10: Effect of 25µM BSO incubation over time on progesterone synthesis.  The cells 
were treated with 25 µM BSO for a 24 hour period every 4 days for 28 days. Cells were then 
washed, re-plated, and 24 hours later were stimulated with LH for 1 hour. Data are shown as ng 
of progesterone per 106 cells (A) and as percent of control cells given 0 µM BSO (B), cultured 




Figure 11: Effect of 50µM BSO incubation over time on progesterone synthesis. The cells 
were treated with 50 µM BSO for a 24 hour period every 4 days for 28 days. Cells were then 
washed, re-plated, and 24 hours later were stimulated with LH for 1 hour. Data are shown as ng 
of progesterone per 106 cells (A) and as percent of control cells given 0 µM BSO (B), cultured 




Figure 12: Effect of 100µM BSO incubation over time on progesterone synthesis. The cells 
were treated with 100 µM BSO for a 24 hour period every 4 days for 28 days. Cells were then 
washed, re-plated, and 24 hours later were stimulated with LH for 1 hour. Data are shown as ng 
of progesterone per 106 cells (A) and as percent of control cells given 0 µM BSO (B), cultured 




Figure 13: Effect of long-term (0-28 days) BSO incubation on intracellular GSH and 
progesterone as percent of control. Cells were cultured in M-199 culture medium in the 
presence of 0, 25, 50, or 100 µl/ml BSO, which was given for 24 hours in 4-day intervals. 
Following BSO treatment, cells were then washed, removed using trypsin, and assayed for GSH. 
Remaining cells not assayed were then re-plated, and 24 hours later were stimulated with LH for 
1 hour for progesterone assay. Figures A and B show GSH and progesterone levels respectively 
throughout cell culture. 
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Days	  of	  
Culture	   0	  µM	  BSO	   25	  µM	  BSO	   50	  µM	  BSO	   100	  µM	  BSO	   P	  Value	  
1	   3.975	   3.124	   2.869	   2.671	   0.549	  
8	   4.315	   4.129	   3.595	   4.078	   0.871	  
12	   5.404	   3.235	   3.901	   3.874	   0.496	  
28	   3.201	   3.043	   2.451	   1.873	   0.034	  
Table 1: Intracellular GSH as a function of BSO concentration and days of cell culture. 
 

















Culture	   0	  µM	  BSO	   25	  µM	  BSO	   50	  µM	  BSO	   100	  µM	  BSO	   P	  Value	  
1	   3.993	   4.577	   4.121	   3.773	   0.087	  
8	   2.914	   3.259	   2.614	   2.506	   0.930	  
12	   2.659	   1.975	   1.716	   1.609	   0.287	  
28	   1.631	   0.985	   0.899	   1.154	   0.615	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